Sorbinil

Sorbinil
Names
	IUPAC name (4S)-6-Fluoro-2,3-dihydro-2’H,5’H-spiro[chromene-4,4’-imidazolidine]-2’,5’-dione
	Other names (S)-6-Fluorospiro(chroman-4,4'-imidazolidine)-2',5'-dione; CP 45634
Identifiers
CAS Number	68367-52-2;
3D model (JSmol)	Interactive image;
ChEMBL	ChEMBL7681;
ChemSpider	298991;
ECHA InfoCard	100.210.173
IUPHAR/BPS	7415;
KEGG	D05893;
PubChem CID	337359;
UNII	G4186B906P ;
CompTox Dashboard (EPA)	DTXSID0023587 ;
	InChI InChI=1S/C11H9FN2O3/c12-6-1-2-8-7(5-6)11(3-4-17-8)9(15)13-10(16)14-11/h1-2,5H,3-4H2,(H2,13,14,15,16)/t11-/m0/s1;
	SMILES Fc3ccc2OCC[C@@]1(C(=O)NC(=O)N1)c2c3;
Properties[1]
Chemical formula	C11H9FN2O3
Molar mass	236.202 g·mol−1
Appearance	White to off-white powder
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
	Infobox references

Sorbinil (INN) is an aldose reductase inhibitor being investigated for treatment of diabetic complications including neuropathy and retinopathy.[3] Aldose reductase is an enzyme present in lens and brain that gets rid of excess glucose by converting it to sorbitol. Sorbitol accumulation can lead to the development of cataracts in the lens and neuropathy in peripheral nerves. Sorbinil has been shown to inhibit aldose reductase in human brain[4] and placenta[5] and calf[6] and rat lens.[5] Sorbinil reduced sorbitol accumulation in rat lens and sciatic nerve of diabetic rats orally administered 0.25 mg/kg sorbinil.[5]

References

Sorbinil at Sigma-Aldrich
"International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary names (Rec. INN): List 25" (PDF). World Health Organization. 1985. Retrieved 11 November 2016.
MacCari, R; Del Corso, A; Giglio, M; Moschini, R; Mura, U; Ottanà, R (2011). "In vitro evaluation of 5-arylidene-2-thioxo-4-thiazolidinones active as aldose reductase inhibitors". Bioorganic & Medicinal Chemistry Letters. 21 (1): 200–3. doi:10.1016/j.bmcl.2010.11.041. PMID 21129963.
O'Brien MM; et al. (1982). "Inhibition of human brain aldose reductase and hexonate dehydrogenase by alrestatin and sorbinil". J Neurochem. 39: 810–4. doi:10.1111/j.1471-4159.1982.tb07964.x. PMID 6808090.
Kinoshita JH; et al. (1979). "Aldose reductase in diabetic complications of the eye". Metabolism. 28 (suppl 1): 462–9. doi:10.1016/0026-0495(79)90057-x. PMID 45423.
Peterson MJ; et al. (1979). "CP45,634: A novel aldose reductase inhibitor that inhibits polyol pathway activity in diabetic and galactosemic rats". Metabolism. 28 (Suppl 1): 456–61. doi:10.1016/0026-0495(79)90056-8. PMID 122297.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Sorbinil at Sigma-Aldrich

[INN-2] "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary names (Rec. INN): List 25" (PDF). World Health Organization. 1985. Retrieved 11 November 2016.

[3] MacCari, R; Del Corso, A; Giglio, M; Moschini, R; Mura, U; Ottanà, R (2011). "In vitro evaluation of 5-arylidene-2-thioxo-4-thiazolidinones active as aldose reductase inhibitors". Bioorganic & Medicinal Chemistry Letters. 21 (1): 200–3. doi:10.1016/j.bmcl.2010.11.041. PMID 21129963.

[4] O'Brien MM; et al. (1982). "Inhibition of human brain aldose reductase and hexonate dehydrogenase by alrestatin and sorbinil". J Neurochem. 39: 810–4. doi:10.1111/j.1471-4159.1982.tb07964.x. PMID 6808090.

[Kin79-5] Kinoshita JH; et al. (1979). "Aldose reductase in diabetic complications of the eye". Metabolism. 28 (suppl 1): 462–9. doi:10.1016/0026-0495(79)90057-x. PMID 45423.

[6] Peterson MJ; et al. (1979). "CP45,634: A novel aldose reductase inhibitor that inhibits polyol pathway activity in diabetic and galactosemic rats". Metabolism. 28 (Suppl 1): 456–61. doi:10.1016/0026-0495(79)90056-8. PMID 122297.